Prevention of Stroke in Patients with Silent Cerebrovascular Disease: A Scientific Statement for Healthcare Professionals from the American Heart Association/American Stroke Association

Stroke

Volumn 48, Issue 2, 2017, Pages e44-e71

  Smith, Eric E ^a   Saposnik, Gustavo ^a   Biessels, Geert Jan ^a   Doubal, Fergus N ^a   Fornage, Myriam ^a   Gorelick, Philip B ^a   Greenberg, Steven M ^a   Higashida, Randall T ^a   Kasner, Scott E ^a   Seshadri, Sudha ^a  

^a NONE

Author keywords

AHA Scientific Statements; anticoagulants; brain infarction; cerebrovascular disorders; prevention and control; white matter

Indexed keywords

AGING; ANTICOAGULATION; ARTICLE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; HUMAN; MEDICAL SOCIETY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIMARY PREVENTION; PRIORITY JOURNAL; RESEARCH; RISK FACTOR; SILENT CEREBROVASCULAR DISEASE; WHITE MATTER; CEREBROVASCULAR DISORDERS; CLINICAL TRIAL (TOPIC); DIAGNOSTIC IMAGING; HEALTH CARE PERSONNEL; NEUROIMAGING; PROCEDURES; STANDARDS; STROKE; UNITED STATES;

AMERICAN HEART ASSOCIATION; CEREBROVASCULAR DISORDERS; CLINICAL TRIALS AS TOPIC; HEALTH PERSONNEL; HUMANS; NEUROIMAGING; RISK FACTORS; STROKE; UNITED STATES;

EID: 85010868829     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STR.0000000000000116     Document Type: Article

References (184)

1. Vermeer SE, Longstreth WT Jr, Koudstaal PJ. Silent brain infarcts: a systematic review. Lancet Neurol. 2007;6:611-619. doi: 10.1016/ S1474-4422(07)70170-9.
2. Leary MC, Saver JL. Annual incidence of frst silent stroke in the United States: a preliminary estimate. Cerebrovasc Dis. 2003;16:280-285. doi: 71128.
3. Vernooij MW, Ikram MA, Tanghe HL, Vincent AJ, Hofman A, Krestin GP, Niessen WJ, Breteler MM, van der Lugt A. Incidental findings on brain MRI in the general population. N Engl J Med. 2007;357:1821-1828. doi: 10.1056/NEJMoa070972.
4. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 2010;9:689-701. doi: 10.1016/S1474-4422(10)70104-6.
5. Greenberg SM, Vernooij MW, Cordonnier C, Viswanathan A, Al-Shahi Salman R, Warach S, Launer LJ, Van Buchem MA, Breteler MM; Microbleed Study Group. Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol. 2009;8:165-174. doi: 10.1016/S1474-4422(09)70013-4.
6. Sacco RL, Kasner SE, Broderick JP, Caplan LR, Connors JJ, Culebras A, Elkind MS, George MG, Hamdan AD, Higashida RT, Hoh BL, Janis LS, Kase CS, Kleindorfer DO, Lee JM, Moseley ME, Peterson ED, Turan TN, Valderrama AL, Vinters HV; on behalf of the American Heart Association Stroke Council, Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular and Stroke Nursing; Council on Epidemiology and Prevention; Council on Peripheral Vascular Disease; Council on Nutrition, Physical Activity and Metabolism. An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44:2064-2089. doi: 10.1161/STR.0b013e318296aeca.
7. Prins ND, van Dijk EJ, den Heijer T, Vermeer SE, Jolles J, Koudstaal PJ, Hofman A, Breteler MM. Cerebral small-vessel disease and decline in information processing speed, executive function and memory. Brain. 2005;128(pt 9):2034-2041. doi: 10.1093/brain/awh553.
8. Longstreth WT Jr, Manolio TA, Arnold A, Burke GL, Bryan N, Jungreis CA, Enright PL, O'Leary D, Fried L. Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people: the Cardiovascular Health Study. Stroke. 1996;27:1274-1282.
9. Au R, Massaro JM, Wolf PA, Young ME, Beiser A, Seshadri S, D'Agostino RB, DeCarli C. Association of white matter hyperinten-sity volume with decreased cognitive functioning: the Framingham Heart Study. Arch Neurol. 2006;63:246-250. doi: 10.1001/archneur. 63.2.246.
10. Vermeer SE, Hollander M, van Dijk EJ, Hofman A, Koudstaal PJ, Breteler MM; Rotterdam Scan Study. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke. 2003;34:1126-1129. doi: 10.1161/01. STR.0000068408.82115.D2.
11. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003;348:1215-1222. doi: 10.1056/NEJMoa022066.
12. Debette S, Beiser A, DeCarli C, Au R, Himali JJ, Kelly-Hayes M, Romero JR, Kase CS, Wolf PA, Seshadri S. Association of MRI markers of vascular brain injury with incident stroke, mild cognitive impairment, dementia, and mortality: the Framingham Offspring Study. Stroke. 2010;41:600-606. doi: 10.1161/STROKEAHA.109.570044.
13. Bernick C, Kuller L, Dulberg C, Longstreth WT Jr, Manolio T, Beauchamp N, Price T; Cardiovascular Health Study Collaborative Reseach Group. Silent MRI infarcts and the risk of future stroke: the Cardiovascular Health Study. Neurology. 2001;57:1222-1229.
14. Longstreth WT Jr. Brain vascular disease overt and covert. Stroke. 2005;36:2062-2063.
15. Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, Launer LJ, Laurent S, Lopez OL, Nyenhuis D, Petersen RC, Schneider JA, Tzourio C, Arnett DK, Bennett DA, Chui HC, Higashida RT, Lindquist R, Nilsson PM, Roman GC, Sellke FW, Seshadri S; on behalf of the American Heart Association Stroke Council, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42:2672-2713. doi: 10.1161/STR.0b013e3182299496.
16. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, Lindley RI, O'Brien JT, Barkhof F, Benavente OR, Black SE, Brayne C, Breteler M, Chabriat H, Decarli C, de Leeuw FE, Doubal F, Duering M, Fox NC, Greenberg S, Hachinski V, Kilimann I, Mok V, Oostenbrugge Rv, Pantoni L, Speck O, Stephan BC, Teipel S, Viswanathan A, Werring D, Chen C, Smith C, van Buchem M, Norrving B, Gorelick PB, Dichgans M; STandards for ReportIng Vascular changes on nEuroimaging (STRIVE v1). Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12:822-838. doi: 10.1016/S1474-4422(13)70124-8.
17. Debette S, Markus HS. The clinical importance of white matter hyper-intensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ. 2010;341:c3666.
18. Cordonnier C, Al-Shahi Salman R, Wardlaw J. Spontaneous brain micro-bleeds: systematic review, subgroup analyses and standards for study design and reporting. Brain. 2007;130(pt 8):1988-2003. doi: 10.1093/ brain/awl387.
19. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol. 1987;149:351-356. doi: 10.2214/ajr.149.2.351.
20. American College of Radiology. ACR-ASNR-SPR practice parameter for the performance and interpretation of magnetic resonance imaging of the brain. http://www.acr.org/~/media/ACR/Documents/PGTS/guide-lines/MRI-Brain.pdf. Accessed November 3, 2015.
21. Wardlaw JM, Brindle W, Casado AM, Shuler K, Henderson M, Thomas B, Macfarlane J, Muñoz Maniega S, Lymer K, Morris Z, Pernet C, Nailon W, Ahearn T, Mumuni AN, Mugruza C, McLean J, Chakirova G, Tao YT, Simpson J, Stanfeld AC, Johnston H, Parikh J, Royle NA, De Wilde J, Bastin ME, Weir N, Farrall A, Valdes Hernandez MC; SINAPSE Collaborative Group. A systematic review of the utility of 1.5 versus 3 Tesla magnetic resonance brain imaging in clinical practice and research. Eur Radiol. 2012;22:2295-2303. doi: 10.1007/ s00330-012-2500-8.
22. Hachinski V, Iadecola C, Petersen RC, Breteler MM, Nyenhuis DL, Black SE, Powers WJ, DeCarli C, Merino JG, Kalaria RN, Vinters HV, Holtzman DM, Rosenberg GA, Wallin A, Dichgans M, Marler JR, Leblanc GG. National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards [published correction appears in Stroke. 2007;38:1118]. Stroke. 2006;37:2220-2241. doi: 10.1161/01.STR.0000237236.88823.47.
23. Potter GM, Marlborough FJ, Wardlaw JM. Wide variation in defni-tion, detection, and description of lacunar lesions on imaging. Stroke. 2011;42:359-366. doi: 10.1161/STROKEAHA.110.594754.
24. Zhu YC, Dufouil C, Tzourio C, Chabriat H. Silent brain infarcts: a review of MRI diagnostic criteria. Stroke. 2011;42:1140-1145. doi: 10.1161/ STROKEAHA.110.600114.
25. Vermeer SE, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MM. Prevalence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke. 2002;33:21-25.
26. Moreau F, Patel S, Lauzon ML, McCreary CR, Goyal M, Frayne R, Demchuk AM, Coutts SB, Smith EE. Cavitation after acute symptomatic lacunar stroke depends on time, location, and MRI sequence. Stroke. 2012;43:1837-1842. doi: 10.1161/STROKEAHA.111.647859.
27. Bokura H, Kobayashi S, Yamaguchi S. Distinguishing silent lacunar infarction from enlarged Virchow-Robin spaces: a magnetic resonance imaging and pathological study. J Neurol. 1998;245:116-122.
28. Potter GM, Doubal FN, Jackson CA, Chappell FM, Sudlow CL, Dennis MS, Wardlaw JM. Counting cavitating lacunes underestimates the burden of lacunar infarction. Stroke. 2010;41:267-272. doi: 10.1161/ STROKEAHA.109.566307.
29. Smith EE, Schneider JA, Wardlaw JM, Greenberg SM. Cerebral micro-infarcts: the invisible lesions. Lancet Neurol. 2012;11:272-282. doi: 10.1016/S1474-4422(11)70307-6.
30. Brundel M, de Bresser J, van Dillen JJ, Kappelle LJ, Biessels GJ. Cerebral microinfarcts: a systematic review of neuropathological studies. J Cereb Blood Flow Metab. 2012;32:425-436. doi: 10.1038/ jcbfm.2011.200.
31. van Dalen JW, Scuric EE, van Veluw SJ, Caan MW, Nederveen AJ, Biessels GJ, van Gool WA, Richard E. Cortical microinfarcts detected in vivo on 3 Tesla MRI: clinical and radiological correlates. Stroke. 2015;46:255-257. doi: 10.1161/STROKEAHA.114.007568.
32. DeCarli C, Fletcher E, Ramey V, Harvey D, Jagust WJ. Anatomical mapping of white matter hyperintensities (WMH): exploring the relationships between periventricular WMH, deep WMH, and total WMH burden. Stroke. 2005;36:50-55. doi: 10.1161/01.STR.0000150668.58689.f2.
33. Schiffmann R, van der Knaap MS. Invited article: an MRI-based approach to the diagnosis of white matter disorders. Neurology. 2009;72:750-759. doi: 10.1212/01.wnl.0000343049.00540.c8.
34. Hesselink JR. Differential diagnostic approach to MR imaging of white matter diseases. Top Magn Reson Imaging. 2006;17:243-263. doi: 10.1097/01.rmr.0000248666.91834.af.
35. Wahlund LO, Barkhof F, Fazekas F, Bronge L, Augustin M, Sjögren M, Wallin A, Ader H, Leys D, Pantoni L, Pasquier F, Erkinjuntti T, Scheltens P; European Task Force on Age-Related White Matter Changes. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke. 2001;32:1318-1322.
36. Kapeller P, Barber R, Vermeulen RJ, Adèr H, Scheltens P, Freidl W, Almkvist O, Moretti M, del Ser T, Vaghfeldt P, Enzinger C, Barkhof F, Inzitari D, Erkinjunti T, Schmidt R, Fazekas F; European Task Force of Age Related White Matter Changes. Visual rating of age-related white matter changes on magnetic resonance imaging: scale comparison, interrater agreement, and correlations with quantitative measurements. Stroke. 2003;34:441-445.
37. Kobayashi S, Okada K, Koide H, Bokura H, Yamaguchi S. Subcortical silent brain infarction as a risk factor for clinical stroke. Stroke. 1997;28:1932-1939.
38. Schmidt R, Fazekas F, Hayn M, Schmidt H, Kapeller P, Roob G, Offenbacher H, Schumacher M, Eber B, Weinrauch V, Kostner GM, Esterbauer H. Risk factors for microangiopathy-related cerebral damage in the Austrian stroke prevention study. J Neurol Sci. 1997;152:15-21.
39. Price TR, Manolio TA, Kronmal RA, Kittner SJ, Yue NC, Robbins J, Anton-Culver H, O'Leary DH. Silent brain infarction on magnetic resonance imaging and neurological abnormalities in community-dwelling older adults: the Cardiovascular Health Study: CHS Collaborative Research Group. Stroke. 1997;28:1158-1164.
40. Longstreth WT Jr. Brain abnormalities in the elderly: frequency and predictors in the United States (the Cardiovascular Health Study): Cardiovascular Health Study Collaborative Research Group. J Neural Transm Suppl. 1998;53:9-16.
41. Chen X, Wen W, Anstey KJ, Sachdev PS. Prevalence, incidence, and risk factors of lacunar infarcts in a community sample. Neurology. 2009;73:266-272. doi: 10.1212/WNL.0b013e3181aa52ea.
42. Longstreth WT Jr, Dulberg C, Manolio TA, Lewis MR, Beauchamp NJ Jr, O'Leary D, Carr J, Furberg CD. Incidence, manifestations, and predictors of brain infarcts defned by serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study. Stroke. 2002;33:2376-2382.
43. Vermeer SE, Den Heijer T, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MM; Rotterdam Scan Study. Incidence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke. 2003;34:392-396.
44. Gouw AA, van der Flier WM, Fazekas F, van Straaten EC, Pantoni L, Poggesi A, Inzitari D, Erkinjuntti T, Wahlund LO, Waldemar G, Schmidt R, Scheltens P, Barkhof F; LADIS Study Group. Progression of white matter hyperintensities and incidence of new lacunes over a 3-year period: the Leukoaraiosis and Disability study. Stroke. 2008;39:1414-1420. doi: 10.1161/STROKEAHA.107.498535.
45. Das RR, Seshadri S, Beiser AS, Kelly-Hayes M, Au R, Himali JJ, Kase CS, Benjamin EJ, Polak JF, O'Donnell CJ, Yoshita M, D'Agostino RB Sr, DeCarli C, Wolf PA. Prevalence and correlates of silent cerebral infarcts in the Framingham Offspring Study. Stroke. 2008;39:2929-2935. doi: 10.1161/STROKEAHA.108.516575.
46. Fanning JP, Wong AA, Fraser JF. The epidemiology of silent brain infarction: a systematic review of population-based cohorts. BMC Med. 2014;12:119. doi: 10.1186/s12916-014-0119-0.
47. Prabhakaran S, Wright CB, Yoshita M, Delapaz R, Brown T, DeCarli C, Sacco RL. Prevalence and determinants of subclinical brain infarction: the Northern Manhattan Study. Neurology. 2008;70:425-430. doi: 10.1212/01.wnl.0000277521.66947.e5.
48. Fornage M, Debette S, Bis JC, Schmidt H, Ikram MA, Dufouil C, Sigurdsson S, Lumley T, DeStefano AL, Fazekas F, Vrooman HA, Shibata DK, Maillard P, Zijdenbos A, Smith AV, Gudnason H, de Boer R, Cushman M, Mazoyer B, Heiss G, Vernooij MW, Enzinger C, Glazer NL, Beiser A, Knopman DS, Cavalieri M, Niessen WJ, Harris TB, Petrovic K, Lopez OL, Au R, Lambert JC, Hofman A, Gottesman RF, Garcia M, Heckbert SR, Atwood LD, Catellier DJ, Uitterlinden AG, Yang Q, Smith NL, Aspelund T, Romero JR, Rice K, Taylor KD, Nalls MA, Rotter JI, Sharrett R, van Duijn CM, Amouyel P, Wolf PA, Gudnason V, van der Lugt A, Boerwinkle E, Psaty BM, Seshadri S, Tzourio C, Breteler MM, Mosley TH, Schmidt R, Longstreth WT, DeCarli C, Launer LJ. Genome-wide association studies of cerebral white matter lesion burden: the CHARGE consortium. Ann Neurol. 2011;69:928-939. doi: 10.1002/ ana.22403.
49. Atwood LD, Wolf PA, Heard-Costa NL, Massaro JM, Beiser A, D'Agostino RB, DeCarli C. Genetic variation in white matter hyperin-tensity volume in the Framingham study. Stroke. 2004;35:1609-1613. doi: 10.1161/01.STR.0000129643.77045.10.
50. Verhaaren BF, Debette S, Bis JC, Smith JA, Ikram MK, Adams HH, Beecham AH, Rajan KB, Lopez LM, Barral S, van Buchem MA, van der Grond J, Smith AV, Hegenscheid K, Aggarwal NT, de Andrade M, Atkinson EJ, Beekman M, Beiser AS, Blanton SH, Boerwinkle E, Brickman AM, Bryan RN, Chauhan G, Chen CP, Chouraki V, de Craen AJ, Crivello F, Deary IJ, Deelen J, De Jager PL, Dufouil C, Elkind MS, Evans DA, Freudenberger P, Gottesman RF, Guason V, Habes M, Heckbert SR, Heiss G, Hilal S, Hofer E, Hofman A, Ibrahim-Verbaas CA, Knopman DS, Lewis CE, Liao J, Liewald DC, Luciano M, van der Lugt A, Martinez OO, Mayeux R, Mazoyer B, Nalls M, Nauck M, Niessen WJ, Oostra BA, Psaty BM, Rice KM, Rotter JI, von Sarnowski B, Schmidt H, Schreiner PJ, Schuur M, Sidney SS, Sigurdsson S, Slagboom PE, Stott DJ, van Swieten JC, Teumer A, Töglhofer AM, Traylor M, Trompet S, Turner ST, Tzourio C, Uh HW, Uitterlinden AG, Vernooij MW, Wang JJ, Wong TY, Wardlaw JM, Windham BG, Wittfeld K, Wolf C, Wright CB, Yang Q, Zhao W, Zijdenbos A, Jukema JW, Sacco RL, Kardia SL, Amouyel P, Mosley TH, Longstreth WT Jr, DeCarli CC, van Duijn CM, Schmidt R, Launer LJ, Grabe HJ, Seshadri SS, Ikram MA, Fornage M. Multiethnic genome-wide association study of cerebral white matter hyperintensities on MRI. Circ Cardiovasc Genet. 2015;8:398-409. doi: 10.1161/CIRCGENETICS.114.000858.
51. Allan CL, Zsoldos E, Filippini N, Sexton CE, Topiwala A, Valkanova V, Singh-Manoux A, Tabák AG, Shipley MJ, Mackay C, Ebmeier KP, Kivimäki M. Lifetime hypertension as a predictor of brain structure in older adults: cohort study with a 28-year follow-up. Br J Psychiatry. 2015;206:308-315. doi: 10.1192/bjp.bp.114.153536.
52. Swan GE, DeCarli C, Miller BL, Reed T, Wolf PA, Jack LM, Carmelli D. Association of midlife blood pressure to late-life cognitive decline and brain morphology. Neurology. 1998;51:986-993.
53. Pavese N, Canapicchi R, Nuti A, Bibbiani F, Lucetti C, Collavoli P, Bonuccelli U. White matter MRI hyperintensities in a hundred and twenty-nine consecutive migraine patients. Cephalalgia. 1994;14:342-345.
54. Hamedani AG, Rose KM, Peterlin BL, Mosley TH, Coker LH, Jack CR, Knopman DS, Alonso A, Gottesman RF. Migraine and white matter hyperintensities: the ARIC MRI study. Neurology. 2013;81:1308-1313. doi: 10.1212/WNL.0b013e3182a8235b.
55. Jorm AF, Anstey KJ, Christensen H, de Plater G, Kumar R, Wen W, Sachdev P. MRI hyperintensities and depressive symptoms in a community sample of individuals 60-64 years old. Am J Psychiatry. 2005;162:699-705. doi: 10.1176/appi.ajp.162.4.699.
56. Breeze JL, Hesdorffer DC, Hong X, Frazier JA, Renshaw PF. Clinical significance of brain white matter hyperintensities in young adults with psychiatric illness. Harv Rev Psychiatry. 2003;11:269-283.
57. Hopkins RO, Beck CJ, Burnett DL, Weaver LK, Victoroff J, Bigler ED. Prevalence of white matter hyperintensities in a young healthy population. J Neuroimaging. 2006;16:243-251.
58. DeCarli C, Miller BL, Swan GE, Reed T, Wolf PA, Garner J, Jack L, Carmelli D. Predictors of brain morphology for the men of the NHLBI twin study. Stroke. 1999;30:529-536.
59. Dufouil C, de Kersaint-Gilly A, Besançon V, Levy C, Auffray E, Brunnereau L, Alpérovitch A, Tzourio C. Longitudinal study of blood pressure and white matter hyperintensities: the E VA MRI cohort. Neurology. 2001;56:921-926.
60. Mosley TH Jr, Knopman DS, Catellier DJ, Bryan N, Hutchinson RG, Grothues CA, Folsom AR, Cooper LS, Burke GL, Liao D, Szklo M. Cerebral MRI findings and cognitive functioning: the Atherosclerosis Risk in Communities study. Neurology. 2005;64:2056-2062. doi: 10.1212/01.WNL.0000165985.97397.88.
61. Brickman AM, Schupf N, Manly JJ, Luchsinger JA, Andrews H, Tang MX, Reitz C, Small SA, Mayeux R, DeCarli C, Brown TR. Brain morphology in older African Americans, Caribbean Hispanics, and whites from northern Manhattan. Arch Neurol. 2008;65:1053-1061. doi: 10.1001/archneur.65.8.1053.
62. Del Brutto OH, Mera RM, Del Brutto VJ, Zambrano M, Lama J. White matter hyperintensities of presumed vascular origin: a population-based study in rural Ecuador (the Atahualpa Project). Int J Stroke. 2015;10:372-375. doi: 10.1111/ijs.12417.
63. Liao D, Cooper L, Cai J, Toole J, Bryan N, Burke G, Shahar E, Nieto J, Mosley T, Heiss G. The prevalence and severity of white matter lesions, their relationship with age, ethnicity, gender, and cardiovascular disease risk factors: the ARIC Study. Neuroepidemiology. 1997;16:149-162.
64. Scheltens P, Barkhof F, Valk J, Algra PR, van der Hoop RG, Nauta J, Wolters EC. White matter lesions on magnetic resonance imaging in clinically diagnosed Alzheimer's disease: evidence for heterogeneity. Brain. 1992;115(pt 3):735-748.
65. Wardlaw JM, Ferguson KJ, Graham C. White matter hyperintensities and rating scales-observer reliability varies with lesion load. J Neurol. 2004;251:584-590. doi: 10.1007/s00415-004-0371-x.
66. Sandeman EM, Hernandez Mdel C, Morris Z, Bastin ME, Murray C, Gow AJ, Corley J, Henderson R, Deary IJ, Starr JM, Wardlaw JM. Incidental findings on brain MR imaging in older community-dwelling subjects are common but serious medical consequences are rare: a cohort study. PLoS One. 2013;8:e71467. doi: 10.1371/journal.pone.0071467.
67. Fazekas F, Schmidt R, Kleinert R, Kapeller P, Roob G, Flooh E. The spectrum of age-associated brain abnormalities: their measurement and histopathological correlates. J Neural Transm Suppl. 1998;53:31-39.
68. Söderlund H, Nyberg L, Adolfsson R, Nilsson LG, Launer LJ. High prevalence of white matter hyperintensities in normal aging: relation to blood pressure and cognition. Cortex. 2003;39:1093-1105.
69. DeCarli C, Murphy DG, Tranh M, Grady CL, Haxby JV, Gillette JA, Salerno JA, Gonzales-Aviles A, Horwitz B, Rapoport SI, Schapiro MB. The effect of white matter hyperintensity volume on brain structure, cognitive performance, and cerebral metabolism of glucose in 51 healthy adults. Neurology. 1995;45:2077-2084.
70. Jeerakathil T, Wolf PA, Beiser A, Massaro J, Seshadri S, D'Agostino RB, DeCarli C. Stroke risk profle predicts white matter hyperinten-sity volume: the Framingham study. Stroke. 2004;35:1857-1861. doi: 10.1161/01.STR.0000135226.53499.85.
71. Smith EE, Egorova S, Blacker D, Killiany RJ, Muzikansky A, Dickerson BC, Tanzi RE, Albert MS, Greenberg SM, Guttmann CR. Magnetic resonance imaging white matter hyperintensities and brain volume in the prediction of mild cognitive impairment and dementia. Arch Neurol. 2008;65:94-100. doi: 10.1001/archneurol.2007.23.
72. Rost NS, Rahman RM, Biff A, Smith EE, Kanakis A, Fitzpatrick K, Lima F, Worrall BB, Meschia JF, Brown RD Jr, Brott TG, Sorensen AG, Greenberg SM, Furie KL, Rosand J. White matter hyperintensity volume is increased in small vessel stroke subtypes. Neurology. 2010;75:1670-1677. doi: 10.1212/WNL.0b013e3181fc279a.
73. Schmidt R, Fazekas F, Kleinert G, Offenbacher H, Gindl K, Payer F, Freidl W, Niederkorn K, Lechner H. Magnetic resonance imaging signal hyperintensities in the deep and subcortical white matter: a comparative study between stroke patients and normal volunteers. Arch Neurol. 1992;49:825-827.
74. Schmidt R, Schmidt H, Haybaeck J, Loitfelder M, Weis S, Cavalieri M, Seiler S, Enzinger C, Ropele S, Erkinjuntti T, Pantoni L, Scheltens P, Fazekas F, Jellinger K. Heterogeneity in age-related white matter changes. Acta Neuropathol. 2011;122:171-185. doi: 10.1007/ s00401-011-0851-x.
75. Smith EE, O'Donnell M, Dagenais G, Lear SA, Wielgosz A, Sharma M, Poirier P, Stotts G, Black SE, Strother S, Noseworthy MD, Benavente O, Modi J, Goyal M, Batool S, Sanchez K, Hill V, McCreary CR, Frayne R, Islam S, DeJesus J, Rangarajan S, Teo K, Yusuf S; PURE Investigators. Early cerebral small vessel disease and brain volume, cognition, and gait. Ann Neurol. 2015;77:251-261. doi: 10.1002/ana.24320.
76. de Leeuw FE, de Groot JC, Oudkerk M, Witteman JC, Hofman A, van Gijn J, Breteler MM. A follow-up study of blood pressure and cerebral white matter lesions. Ann Neurol. 1999;46:827-833.
77. Roob G, Schmidt R, Kapeller P, Lechner A, Hartung HP, Fazekas F. MRI evidence of past cerebral microbleeds in a healthy elderly population. Neurology. 1999;52:991-994.
78. Jeerakathil T, Wolf PA, Beiser A, Hald JK, Au R, Kase CS, Massaro JM, DeCarli C. Cerebral microbleeds: prevalence and associations with cardiovascular risk factors in the Framingham Study. Stroke. 2004;35:1831-1835. doi: 10.1161/01.STR.0000131809.35202.1b.
79. Kuller LH, Longstreth WT Jr, Arnold AM, Bernick C, Bryan RN, Beauchamp NJ Jr; Cardiovascular Health Study Collaborative Research Group. White matter hyperintensity on cranial magnetic resonance imaging: a predictor of stroke. Stroke. 2004;35:1821-1825. doi: 10.1161/01. STR.0000132193.35955.69.
80. Yakushiji Y, Nishiyama M, Yakushiji S, Hirotsu T, Uchino A, Nakajima J, Eriguchi M, Nanri Y, Hara M, Horikawa E, Kuroda Y. Brain microbleeds and global cognitive function in adults without neurological disorder. Stroke. 2008;39:3323-3328. doi: 10.1161/ STROKEAHA.108.516112.
81. Sveinbjornsdottir S, Sigurdsson S, Aspelund T, Kjartansson O, Eiriksdottir G, Valtysdottir B, Lopez OL, van Buchem MA, Jonsson PV, Gudnason V, Launer LJ. Cerebral microbleeds in the population based AGES-Reykjavik study: prevalence and location. J Neurol Neurosurg Psychiatry. 2008;79:1002-1006. doi: 10.1136/jnnp.2007.121913.
82. Liu PF, Cui YZ, Na J, Gao PY. Cerebral microbleeds: prevalence, distribution and risk factors in northeast population without preceding large-area stroke. Chin Med J (Engl). 2010;123:286-290.
83. van Es AC, van der Grond J, de Craen AJ, Westendorp RG, Bollen EL, Blauw GJ, Greenberg SM, van Buchem MA; PROSPER Study Group. Cerebral microbleeds and cognitive functioning in the PROSPER study. Neurology. 2011;77:1446-1452. doi: 10.1212/WNL.0b013e318232ab1d.
84. Romero JR, Preis SR, Beiser A, DeCarli C, Viswanathan A, Martinez-Ramirez S, Kase CS, Wolf PA, Seshadri S. Risk factors, stroke prevention treatments, and prevalence of cerebral microbleeds in the Framingham Heart Study. Stroke. 2014;45:1492-1494. doi: 10.1161/ STROKEAHA.114.004130.
85. Koennecke HC. Cerebral microbleeds on MRI: prevalence, associations, and potential clinical implications. Neurology. 2006;66:165-171. doi: 10.1212/01.wnl.0000194266.55694.1e.
86. Wiegman AF, Meier IB, Schupf N, Manly JJ, Guzman VA, Narkhede A, Stern Y, Martinez-Ramirez S, Viswanathan A, Luchsinger JA, Greenberg SM, Mayeux R, Brickman AM. Cerebral microbleeds in a multiethnic elderly community: demographic and clinical correlates. J Neurol Sci. 2014;345:125-130. doi: 10.1016/j.jns.2014.07.024.
87. Linn J, Halpin A, Demaerel P, Ruhland J, Giese AD, Dichgans M, van Buchem MA, Bruckmann H, Greenberg SM. Prevalence of superf-cial siderosis in patients with cerebral amyloid angiopathy. Neurology. 2010;74:1346-1350. doi: 10.1212/WNL.0b013e3181dad605.
88. Martinez-Ramirez S, Romero JR, Shoamanesh A, McKee AC, Van Etten E, Pontes-Neto O, Macklin EA, Ayres A, Auriel E, Himali JJ, Beiser AS, DeCarli C, Stein TD, Alvarez VE, Frosch MP, Rosand J, Greenberg SM, Gurol ME, Seshadri S, Viswanathan A. Diagnostic value of lobar microbleeds in individuals without intracerebral hemorrhage. Alzheimers Dement. 2015;11:1480-1488. doi: 10.1016/j.jalz.2015.04.009.
89. Yue NC, Longstreth WT Jr, Elster AD, Jungreis CA, O'Leary DH, Poirier VC. Clinically serious abnormalities found incidentally at MR imaging of the brain: data from the Cardiovascular Health Study. Radiology. 1997;202:41-46. doi: 10.1148/radiology.202.1.8988190.
90. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, Fang MC, Fisher M, Furie KL, Heck DV, Johnston SC, Kasner SE, Kittner SJ, Mitchell PH, Rich MW, Richardson D, Schwamm LH, Wilson JA; on behalf of the American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association [published correction appears in Stroke. 2015;46:e54]. Stroke. 2014;45:2160-2236. doi: 10.1161/STR.0000000000000024.
91. Meschia JF, Bushnell C, Boden-Albala B, Braun LT, Bravata DM, Chaturvedi S, Creager MA, Eckel RH, Elkind MS, Fornage M, Goldstein LB, Greenberg SM, Horvath SE, Iadecola C, Jauch EC, Moore WS, Wilson JA; on behalf of the American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Functional Genomics and Translational Biology; Council on Hypertension. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45:3754-3832. doi: 10.1161/STR.0000000000000046.
92. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial: TOAST: Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24:35-41.
93. Ay H, Benner T, Arsava EM, Furie KL, Singhal AB, Jensen MB, Ayata C, Towfghi A, Smith EE, Chong JY, Koroshetz WJ, Sorensen AG. A computerized algorithm for etiologic classification of ischemic stroke: the Causative Classification of Stroke System. Stroke. 2007;38:2979-2984. doi: 10.1161/STROKEAHA.107.490896.
94. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, Khatri P, McMullan PW Jr, Qureshi AI, Rosenfeld K, Scott PA, Summers DR, Wang DZ, Wintermark M, Yonas H; on behalf of the American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44:870-947. doi: 10.1161/STR.0b013e318284056a.
95. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fbrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 2010;137:263-272.
96. Feinberg WM, Seeger JF, Carmody RF, Anderson DC, Hart RG, Pearce LA. Epidemiologic features of asymptomatic cerebral infarction in patients with nonvalvular atrial fbrillation. Arch Intern Med. 1990;150:2340-2344.
97. Silent brain infarction in nonrheumatic atrial fbrillation: EAFT Study Group: European Atrial Fibrillation Trial. Neurology. 1996;46:159-165.
98. Ezekowitz MD, James KE, Nazarian SM, Davenport J, Broderick JP, Gupta SR, Thadani V, Meyer ML, Bridgers SL. Silent cerebral infarction in patients with nonrheumatic atrial fbrillation: the Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Circulation. 1995;92:2178-2182.
99. Favilla CG, Ingala E, Jara J, Fessler E, Cucchiara B, Messé SR, Mullen MT, Prasad A, Siegler J, Hutchinson MD, Kasner SE. Predictors of finding occult atrial fbrillation after cryptogenic stroke. Stroke. 2015;46:1210-1215. doi: 10.1161/STROKEAHA.114.007763.
100. Brott T, Tomsick T, Feinberg W, Johnson C, Biller J, Broderick J, Kelly M, Frey J, Schwartz S, Blum C, Nelson JJ, Chambless L, Toole J; Asymptomatic Carotid Atherosclerosis Study Investigators. Baseline silent cerebral infarction in the Asymptomatic Carotid Atherosclerosis Study. Stroke. 1994;25:1122-1129.
101. Cao P, Zannetti S, Giordano G, De Rango P, Parlani G, Caputo N. Cerebral tomographic findings in patients undergoing carotid endarterec-tomy for asymptomatic carotid stenosis: short-term and long-term implications. J Vasc Surg. 1999;29:995-1005.
102. Hougaku H, Matsumoto M, Handa N, Maeda H, Itoh T, Tsukamoto Y, Kamada T. Asymptomatic carotid lesions and silent cerebral infarction. Stroke. 1994;25:566-570.
103. Jayasooriya G, Thapar A, Shalhoub J, Davies AH. Silent cerebral events in asymptomatic carotid stenosis. J Vasc Surg. 2011;54:227-236. doi: 10.1016/j.jvs.2011.01.037.
104. Federico A, Di Donato I, Bianchi S, Di Palma C, Taglia I, Dotti MT. Hereditary cerebral small vessel diseases: a review. J Neurol Sci. 2012;322:25-30. doi: 10.1016/j.jns.2012.07.041.
105. Kilarski LL, Rutten-Jacobs LC, Bevan S, Baker R, Hassan A, Hughes DA, Markus HS; UK Young Lacunar Stroke DNA Study. Prevalence of CADASIL and Fabry disease in a cohort of MRI defned younger onset lacunar stroke. PLoS One. 2015;10:e0136352. doi: 10.1371/journal. pone.0136352.
106. Chabriat H, Joutel A, Dichgans M, Tournier-Lasserve E, Bousser MG. Cadasil. Lancet Neurol. 2009;8:643-653. doi: 10.1016/ S1474-4422(09)70127-9.
107. de Leeuw FE, de Groot JC, Oudkerk M, Kors JA, Hofman A, van Gijn J, Breteler MM. Atrial fbrillation and the risk of cerebral white matter lesions. Neurology. 2000;54:1795-1801.
108. Windham BG, Deere B, Griswold ME, Wang W, Bezerra DC, Shibata D, Butler K, Knopman D, Gottesman RF, Heiss G, Mosley TH Jr. Small brain lesions and incident stroke and mortality: a cohort study. Ann Intern Med. 2015;163:22-31. doi: 10.7326/M14-2057.
109. Liao SQ, Li JC, Zhang M, Wang YJ, Li BH, Yin YW, Liu Y, Gao CY, Zhang LL. The association between leukoaraiosis and carotid atherosclerosis: a systematic review and meta-analysis. Int J Neurosci. 2015;125:493-500. doi: 10.3109/00207454.2014.949703.
110. Poels MM, Vernooij MW, Ikram MA, Hofman A, Krestin GP, van der Lugt A, Breteler MM. Prevalence and risk factors of cerebral microbleeds: an update of the Rotterdam scan study. Stroke. 2010;41(suppl):S103-S106. doi: 10.1161/STROKEAHA.110.595181.
111. Knudsen KA, Rosand J, Karluk D, Greenberg SM. Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Neurology. 2001;56:537-539.
112. Hemphill JC 3rd, Greenberg SM, Anderson CS, Becker K, Bendok BR, Cushman M, Fung GL, Goldstein JN, Macdonald RL, Mitchell PH, Scott PA, Selim MH, Woo D; on behalf of the American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2015;46:2032-2060. doi: 10.1161/STR.0000000000000069.
113. Hasegawa Y, Yamaguchi T, Omae T, Woodward M, Chalmers J; PROGRESS CT Substudy Investigators. Effects of perindopril-based blood pressure lowering and of patient characteristics on the progression of silent brain infarct: the Perindopril Protection against Recurrent Stroke Study (PROGRESS) CT Substudy in Japan [published correction appears in Hypertens Res. 2004;27:447]. Hypertens Res. 2004;27:147-156.
114. Weber R, Weimar C, Wanke I, Möller-Hartmann C, Gizewski ER, Blatchford J, Hermansson K, Demchuk AM, Forsting M, Sacco RL, Saver JL, Warach S, Diener HC, Diehl A; PRoFESS Imaging Substudy Group. Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy. Stroke. 2012;43:350-355. doi: 10.1161/ STROKEAHA.111.631739.
115. Nelson M, Reid C, Beilin L, Donnan G, Johnston C, Krum H, Storey E, Tonkin A, McNeil J; Aspirin in Reducing Events in the Elderly (ASPREE) Study Group. Rationale for a trial of low-dose aspirin for the primary prevention of major adverse cardiovascular events and vas cular dementia in the elderly: Aspirin in Reducing Events in the Elderly (ASPREE). Drugs Aging. 2003;20:897-903.
116. Reid CM, Storey E, Wong TY, Woods R, Tonkin A, Wang JJ, Kam A, Janke A, Essex R, Abhayaratna WP, Budge MM; ASPREE Study Group. Aspirin for the prevention of cognitive decline in the elderly: rationale and design of a neuro-vascular imaging study (ENVIS-ion). BMC Neurol. 2012;12:3. doi: 10.1186/1471-2377-12-3.
117. Paraskevas KI, Spence JD, Veith FJ, Nicolaides AN. Identifying which patients with asymptomatic carotid stenosis could ben-eft from intervention. Stroke. 2014;45:3720-3724. doi: 10.1161/ STROKEAHA.114.006912.
118. Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R, Greenland P, Lackland DT, Levy D, O'Donnell CJ, Robinson JG, Schwartz JS, Shero ST, Smith SC Jr, Sorlie P, Stone NJ, Wilson PW, Jordan HS, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli GF. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines [published correction appears in Circulation. 2014;129(suppl 2):S74- S75]. Circulation. 2014;129(suppl 2):S49-S73. doi: 10.1161/01. cir.0000437741.48606.98.
119. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW, Eddleman KM, Jarrett NM, LaBresh K, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli GF. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published corrections appear in Circulation. 2014;129(suppl 2):S46-S48 and Circulation. 2015;132:e396]. Circulation. 2014;129:S1-S45. doi: 10.1161/01.cir.0000437738.63853.7a.
120. Iadecola C. The pathobiology of vascular dementia. Neuron. 2013;80:844-866. doi: 10.1016/j.neuron.2013.10.008.
121. Wardlaw JM, Smith C, Dichgans M. Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging [published correction appears in Lancet Neurol. 2013;12:532]. Lancet Neurol. 2013;12:483-497. doi: 10.1016/S1474-4422(13)70060-7.
122. American Heart Association/American College of Cardiology. CV Risk Calculator. http://my.americanheart.org/cvriskcalculator. Accessed November 9, 2016.
123. Dufouil C, Chalmers J, Coskun O, Besançon V, Bousser MG, Guillon P, MacMahon S, Mazoyer B, Neal B, Woodward M, Tzourio-Mazoyer N, Tzourio C; PROGRESS MRI Substudy Investigators. Effects of blood pressure lowering on cerebral white matter hyper-intensities in patients with stroke: the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy. Circulation. 2005;112:1644-1650. doi: 10.1161/ CIRCULATIONAHA.104.501163.
124. Weber R, Weimar C, Blatchford J, Hermansson K, Wanke I, Möller-Hartmann C, Gizewski ER, Forsting M, Demchuk AM, Sacco RL, Saver JL, Warach S, Diener HC, Diehl A; PRoFESS Imaging Substudy Group. Telmisartan on top of antihypertensive treatment does not prevent progression of cerebral white matter lesions in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) MRI substudy. Stroke. 2012;43:2336-2342. doi: 10.1161/STROKEAHA.111.648576.
125. Xiong Y, Wong A, Cavalieri M, Schmidt R, Chu WW, Liu X, Wong KS, Mok V. Prestroke statins, progression of white matter hyperintensities, and cognitive decline in stroke patients with confuent white matter hyperintensities. Neurotherapeutics. 2014;11:606-611. doi: 10.1007/ s13311-014-0270-5.
126. ten Dam VH, van den Heuvel DM, van Buchem MA, Westendorp RG, Bollen EL, Ford I, de Craen AJ, Blauw GJ; PROSPER Study Group. Effect of pravastatin on cerebral infarcts and white matter lesions. Neurology. 2005;64:1807-1809. doi: 10.1212/01.WNL.0000161844.00797.73.
127. Mok VC, Lam WW, Fan YH, Wong A, Ng PW, Tsoi TH, Yeung V, Wong KS. Effects of statins on the progression of cerebral white matter lesion: post hoc analysis of the ROCAS (Regression of Cerebral Artery Stenosis) study. J Neurol. 2009;256:750-757. doi: 10.1007/s00415-009-5008-7.
128. Launer LJ, Miller ME, Williamson JD, Lazar RM, Gerstein HC, Murray AM, Sullivan M, Horowitz KR, Ding J, Marcovina S, Lovato LC, Lovato J, Margolis KL, O'Connor P, Lipkin EW, Hirsch J, Coker L, Maldjian J, Sunshine JL, Truwit C, Davatzikos C, Bryan RN; ACCORD MIND Investigators. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurol. 2011;10:969-977. doi: 10.1016/S1474-4422(11)70188-0.
129. Cavalieri M, Schmidt R, Chen C, Mok V, de Freitas GR, Song S, Yi Q, Ropele S, Grazer A, Homayoon N, Enzinger C, Loh K, Wong KS, Wong A, Xiong Y, Chang HM, Wong MC, Fazekas F, Eikelboom JW, Hankey GJ; VITATOPS Trial Study Group. B vitamins and magnetic resonance imaging-detected ischemic brain lesions in patients with recent transient ischemic attack or stroke: the VITAmins TO Prevent Stroke (VITATOPS) MRI-substudy. Stroke. 2012;43:3266-3270. doi: 10.1161/ STROKEAHA.112.665703.
130. Richard E, Gouw AA, Scheltens P, van Gool WA. Vascular care in patients with Alzheimer disease with cerebrovascular lesions slows progression of white matter lesions on MRI: the Evaluation of Vascular Care in Alzheimer's Disease (EVA) study. Stroke. 2010;41:554-556. doi: 10.1161/STROKEAHA.109.571281.
131. Gorter JW. Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors: Stroke Prevention In Reversible Ischemia Trial (SPIRIT): European Atrial Fibrillation Trial (EAFT) study groups. Neurology. 1999;53:1319-1327.
132. Richard E, Kuiper R, Dijkgraaf MG, Van Gool WA; Evaluation of Vascular care in Alzheimer's disease. Vascular care in patients with Alzheimer's disease with cerebrovascular lesions: a randomized clinical trial. J Am Geriatr Soc. 2009;57:797-805.
133. Thoonsen H, Richard E, Bentham P, Gray R, van Geloven N, De Haan RJ, Van Gool WA, Nederkoorn PJ. Aspirin in Alzheimer's disease: increased risk of intracerebral hemorrhage: cause for concern? Stroke. 2010;41:2690-2692. doi: 10.1161/STROKEAHA.109.576975.
134. Zheng JJ, Delbaere K, Close JC, Sachdev PS, Lord SR. Impact of white matter lesions on physical functioning and fall risk in older people: a systematic review. Stroke. 2011;42:2086-2090. doi: 10.1161/ STROKEAHA.110.610360.
135. Furie KL, Goldstein LB, Albers GW, Khatri P, Neyens R, Turakhia MP, Turan TN, Wood KA; on behalf of the American Heart Association Stroke Council; Council on Quality of Care and Outcomes Research; Council on Cardiovascular Nursing; Council on Clinical Cardiology; Council on Peripheral Vascular Disease. Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fbrillation: a science advisory for healthcare professionals from the American Heart Association/ American Stroke Association [published corrections appear in Stroke. 2012;43:e181 and Stroke. 2013;44:e20]. Stroke. 2012;43:3442-3453. doi: 10.1161/STR.0b013e318266722a.
136. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fbrillation. Ann Intern Med. 2007;146:857-867.
137. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, Singer DE. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fbrillation. N Engl J Med. 2003;349:1019-1026. doi: 10.1056/NEJMoa022913.
138. Andersen KK, Olsen TS. Reduced poststroke mortality in patients with stroke and atrial fbrillation treated with anticoagulants: results from a Danish quality-control registry of 22,179 patients with ischemic stroke. Stroke. 2007;38:259-263. doi: 10.1161/01.STR.0000254622.52483.03.
139. McGrath ER, Kapral MK, Fang J, Eikelboom JW, Conghaile Aó, O'Conghaile A, Canavan M, O'Donnell MJ; Investigators of the Ontario Stroke Registry. Association of atrial fbrillation with mortality and disability after ischemic stroke [published corrections appear in Neurology. 2013;81:825-832 and Neurology. 2016;86:492]. Neurology. 2013;81:825-832. doi: 10.1212/WNL.0b013e3182a2cc15.
140. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the effcacy and safety of new oral anticoagulants with warfarin in patients with atrial fbrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955-962. doi: 10.1016/S0140-6736(13)62343-0.
141. Fang MC, Go AS, Chang Y, Hylek EM, Henault LE, Jensvold NG, Singer DE. Death and disability from warfarin-associated intracranial and extra-cranial hemorrhages. Am J Med. 2007;120:700-705. doi: 10.1016/j. amjmed.2006.07.034.
142. Kaatz S, Kouides PA, Garcia DA, Spyropolous AC, Crowther M, Douketis JD, Chan AK, James A, Moll S, Ortel TL, Van Cott EM, Ansell J. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors [published correction appears in Am J Hematol. 2012;87:748]. Am J Hematol. 2012;87(suppl 1):S141-S145. doi: 10.1002/ajh.23202.
143. Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A, Diener HC, Donnan GA, Halperin JL, Mahaffey KW, Mas JL, Massaro A, Norrving B, Nessel CC, Paolini JF, Roine RO, Singer DE, Wong L, Califf RM, Fox KA, Hacke W; ROCKET AF Steering Committee Investigators. Rivaroxaban compared with warfarin in patients with atrial fbrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol. 2012;11:315-322. doi: 10.1016/S1474-4422(12)70042-X.
144. Hart RG, Diener HC, Yang S, Connolly SJ, Wallentin L, Reilly PA, Ezekowitz MD, Yusuf S. Intracranial hemorrhage in atrial fbrillation patients during anticoagulation with warfarin or dabi-gatran: the RE-LY trial. Stroke. 2012;43:1511-1517. doi: 10.1161/ STROKEAHA.112.650614.
145. Charidimou A, Kakar P, Fox Z, Werring DJ. Cerebral microbleeds and recurrent stroke risk: systematic review and meta-analysis of prospective ischemic stroke and transient ischemic attack cohorts. Stroke. 2013;44:995-1001. doi: 10.1161/STROKEAHA.111.000038.
146. Nishikawa T, Ueba T, Kajiwara M, Fujisawa I, Miyamatsu N, Yamashita K. Cerebral microbleeds predict frst-ever symptomatic cerebrovascu-lar events. Clin Neurol Neurosurg. 2009;111:825-828. doi: 10.1016/j. clineuro.2009.08.011.
147. Bokura H, Saika R, Yamaguchi T, Nagai A, Oguro H, Kobayashi S, Yamaguchi S. Microbleeds are associated with subsequent hemorrhagic and ischemic stroke in healthy elderly individuals. Stroke. 2011;42:1867-1871. doi: 10.1161/STROKEAHA.110.601922.
148. Greenberg SM, Eng JA, Ning M, Smith EE, Rosand J. Hemorrhage burden predicts recurrent intracerebral hemorrhage after lobar hemorrhage. Stroke. 2004;35:1415-1420. doi: 10.1161/01. STR.0000126807.69758.0e.
149. Soo YO, Yang SR, Lam WW, Wong A, Fan YH, Leung HH, Chan AY, Leung C, Leung TW, Wong LK. Risk vs beneft of anti-thrombotic therapy in ischaemic stroke patients with cerebral microbleeds. J Neurol. 2008;255:1679-1686. doi: 10.1007/s00415-008-0967-7.
150. Biff A, Halpin A, Towfghi A, Gilson A, Busl K, Rost N, Smith EE, Greenberg MS, Rosand J, Viswanathan A. Aspirin and recurrent intra-cerebral hemorrhage in cerebral amyloid angiopathy. Neurology. 2010;75:693-698. doi: 10.1212/WNL.0b013e3181eee40f.
151. Bailey RD, Hart RG, Benavente O, Pearce LA. Recurrent brain hemorrhage is more frequent than ischemic stroke after intracranial hemorrhage. Neurology. 2001;56:773-777.
152. van Etten ES, Auriel E, Haley KE, Ayres AM, Vashkevich A, Schwab KM, Rosand J, Viswanathan A, Greenberg SM, Gurol ME. Incidence of symptomatic hemorrhage in patients with lobar microbleeds. Stroke. 2014;45:2280-2285. doi: 10.1161/STROKEAHA.114.005151.
153. Eckman MH, Wong LK, Soo YO, Lam W, Yang SR, Greenberg SM, Rosand J. Patient-specifc decision-making for warfarin therapy in nonvalvular atrial fbrillation: how will screening with genetics and imaging help? Stroke. 2008;39:3308-3315. doi: 10.1161/ STROKEAHA.108.523159.
154. Nishikawa T, Ueba T, Kajiwara M, Miyamatsu N, Yamashita K. Cerebral microbleeds in patients with intracerebral hemorrhage are associated with previous cerebrovascular diseases and white matter hyperintensity, but not with regular use of antiplatelet agents. Neurol Med Chir (Tokyo). 2009;49:333-338.
155. Song TJ, Kim J, Lee HS, Nam CM, Nam HS, Heo JH, Kim YD. The frequency of cerebral microbleeds increases with CHADS(2) scores in stroke patients with non-valvular atrial fbrillation. Eur J Neurol. 2013;20:502-508. doi: 10.1111/ene.12003.
156. Eckman MH, Singer DE, Rosand J, Greenberg SM. Moving the tipping point: the decision to anticoagulate patients with atrial fbrilla-tion. Circ Cardiovasc Qual Outcomes. 2011;4:14-21. doi: 10.1161/ CIRCOUTCOMES.110.958108.
157. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myo-cardial infarction, and stroke in high risk patients [published correction appears in BMJ. 2002;324:141]. BMJ. 2002;324:71-86.
158. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549-559. doi: 10.1056/ NEJMoa061894.
159. Hackam DG, Woodward M, Newby LK, Bhatt DL, Shao M, Smith EE, Donner A, Mamdani M, Douketis JD, Arima H, Chalmers J, MacMahon S, Tirschwell DL, Psaty BM, Bushnell CD, Aguilar MI, Capampangan DJ, Werring DJ, De Rango P, Viswanathan A, Danchin N, Cheng CL, Yang YH, Verdel BM, Lai MS, Kennedy J, Uchiyama S, Yamaguchi T, Ikeda Y, Mrkobrada M. Statins and intracerebral hemorrhage: collaborative systematic review and meta-analysis. Circulation. 2011;124:2233-2242. doi: 10.1161/ CIRCULATIONAHA.111.055269.
160. Akoudad S, Portegies ML, Koudstaal PJ, Hofman A, van der Lugt A, Ikram MA, Vernooij MW. Cerebral microbleeds are associated with an increased risk of stroke: the Rotterdam Study. Circulation. 2015;132:509-516. doi: 10.1161/CIRCULATIONAHA.115.016261.
161. Reddy VY, Sievert H, Halperin J, Doshi SK, Buchbinder M, Neuzil P, Huber K, Whisenant B, Kar S, Swarup V, Gordon N, Holmes D; PROTECT AF Steering Committee and Investigators. Percutaneous left atrial appendage closure vs warfarin for atrial fbrillation: a randomized clinical trial [published correction appears in JAMA. 2015;313:1061]. JAMA. 2014;312:1988-1998. doi: 10.1001/jama.2014.15192.
162. Demaerschalk BM, Kleindorfer DO, Adeoye OM, Demchuk AM, Fugate JE, Grotta JC, Khalessi AA, Levy EI, Palesch YY, Prabhakaran S, Saposnik G, Saver JL, Smith EE; on behalf of the American Heart Association Stroke Council and Council on Epidemiology and Prevention. Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2016;47:581-641. doi: 10.1161/STR.0000000000000086.
163. Charidimou A, Shoamanesh A, Wilson D, Gang Q, Fox Z, Jäger HR, Benavente OR, Werring DJ. Cerebral microbleeds and postthromboly-sis intracerebral hemorrhage risk: updated meta-analysis. Neurology. 2015;85:927-934. doi: 10.1212/WNL.0000000000001923.
164. Kakuda W, Thijs VN, Lansberg MG, Bammer R, Wechsler L, Kemp S, Moseley ME, Marks MP, Albers GW; DEFUSE Investigators. Clinical importance of microbleeds in patients receiving IV thrombolysis. Neurology. 2005;65:1175-1178. doi: 10.1212/01. wnl.0000180519.27680.0f.
165. Derex L, Nighoghossian N, Hermier M, Adeleine P, Philippeau F, Honnorat J, Yilmaz H, Dardel P, Froment JC, Trouillas P. Thrombolysis for ischemic stroke in patients with old microbleeds on pretreatment MRI. Cerebrovasc Dis. 2004;17:238-241. doi: 10.1159/000076123.
166. Kim HS, Lee DH, Ryu CW, Lee JH, Choi CG, Kim SJ, Suh DC. Multiple cerebral microbleeds in hyperacute ischemic stroke: impact on prevalence and severity of early hemorrhagic transformation after thrombo-lytic treatment. AJR Am J Roentgenol. 2006;186:1443-1449. doi: 10.2214/AJR.04.1933.
167. Gratz PP, El-Koussy M, Hsieh K, von Arx S, Mono ML, Heldner MR, Fischer U, Mattle HP, Zubler C, Schroth G, Gralla J, Arnold M, Jung S. Preexisting cerebral microbleeds on susceptibility-weighted magnetic resonance imaging and post-thrombolysis bleeding risk in 392 patients. Stroke. 2014;45:1684-1688. doi: 10.1161/STROKEAHA.114.004796.
168. Yan S, Jin X, Zhang X, Zhang S, Liebeskind DS, Lou M. Extensive cerebral microbleeds predict parenchymal haemorrhage and poor outcome after intravenous thrombolysis. J Neurol Neurosurg Psychiatry. 2015;86:1267-1272. doi: 10.1136/jnnp-2014-309857.
169. Dannenberg S, Scheitz JF, Rozanski M, Erdur H, Brunecker P, Werring DJ, Fiebach JB, Nolte CH. Number of cerebral microbleeds and risk of intracerebral hemorrhage after intravenous thrombolysis. Stroke. 2014;45:2900-2905. doi: 10.1161/STROKEAHA.114.006448.
170. Moriya Y, Takahashi W, Kijima C, Yutani S, Iijima E, Mizuma A, Honma K, Uesugi T, Ohnuki Y, Nagata E, Yanagimachi N, Takizawa S. Predictors for hemorrhagic transformation with intravenous tissue plasminogen activator in acute ischemic stroke. Tokai J Exp Clin Med. 2013;38:24-27.
171. Kimura K, Aoki J, Shibazaki K, Saji N, Uemura J, Sakamoto Y. New appearance of extraischemic microbleeds on T2∗-weighted magnetic resonance imaging 24 hours after tissue-type plasminogen activator administration. Stroke. 2013;44:2776-2781. doi: 10.1161/ STROKEAHA.113.001778.
172. Fiehler J, Albers GW, Boulanger JM, Derex L, Gass A, Hjort N, Kim JS, Liebeskind DS, Neumann-Haefelin T, Pedraza S, Rother J, Rothwell P, Rovira A, Schellinger PD, Trenkler J; MR STROKE Group. Bleeding Risk Analysis in Stroke Imaging Before ThromboLysis (BRASIL): pooled analysis of T2∗-weighted magnetic resonance imaging data from 570 patients. Stroke. 2007;38:2738-2744. doi: 10.1161/ STROKEAHA.106.480848.
173. Kidwell CS, Saver JL, Villablanca JP, Duckwiler G, Fredieu A, Gough K, Leary MC, Starkman S, Gobin YP, Jahan R, Vespa P, Liebeskind DS, Alger JR, Vinuela F. Magnetic resonance imaging detection of microbleeds before thrombolysis: an emerging application. Stroke. 2002;33:95-98.
174. Turc G, Sallem A, Moulin S, Tisserand M, Machet A, Edjlali M, Baron JC, Leclerc X, Leys D, Mas JL, Cordonnier C, Oppenheim C. Microbleed status and 3-month outcome after intravenous thrombolysis in 717 patients with acute ischemic stroke. Stroke. 2015;46:2458-2463. doi: 10.1161/STROKEAHA.115.009290.
175. Akins PT, Amar AP, Pakbaz RS, Fields JD; SWIFT Investigators. Complications of endovascular treatment for acute stroke in the SWIFT trial with Solitaire and Merci devices. AJNR Am J Neuroradiol. 2014;35:524-528. doi: 10.3174/ajnr.A3707.
176. Shi ZS, Duckwiler GR, Jahan R, Tateshima S, Gonzalez NR, Szeder V, Saver JL, Kim D, Ali LK, Starkman S, Vespa PM, Salamon N, Villablanca JP, Viñuela F, Feng L, Loh Y, Liebeskind DS. Mechanical thrombectomy for acute ischemic stroke with cerebral microbleeds. J Neurointerv Surg. 2016;8:563-567. doi: 10.1136/neurintsurg-2015-011765.
177. Diedler J, Ahmed N, Sykora M, Uyttenboogaart M, Overgaard K, Luijckx GJ, Soinne L, Ford GA, Lees KR, Wahlgren N, Ringleb P. Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset. Stroke. 2010;41:288-294. doi: 10.1161/STROKEAHA.109.559724.
178. DeBaun MR, Gordon M, McKinstry RC, Noetzel MJ, White DA, Sarnaik SA, Meier ER, Howard TH, Majumdar S, Inusa BP, Telfer PT, Kirby-Allen M, McCavit TL, Kamdem A, Airewele G, Woods GM, Berman B, Panepinto JA, Fuh BR, Kwiatkowski JL, King AA, Fixler JM, Rhodes MM, Thompson AA, Heiny ME, Redding-Lallinger RC, Kirkham FJ, Dixon N, Gonzalez CE, Kalinyak KA, Quinn CT, Strouse JJ, Miller JP, Lehmann H, Kraut MA, Ball WS Jr, Hirtz D, Casella JF. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med. 2014;371:699-710. doi: 10.1056/NEJMoa1401731.
179. DeBaun MR. The challenge of creating an evidence-based guideline for sickle cell disease. JAMA. 2014;312:1004-1005. doi: 10.1001/ jama.2014.11103.
180. Yawn BP, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell KL, James AH, Jordan L, Lanzkron SM, Lottenberg R, Savage WJ, Tanabe PJ, Ware RE, Murad MH, Goldsmith JC, Ortiz E, Fulwood R, Horton A, John-Sowah J. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members [published corrections appear in JAMA. 2014;312:1932 and JAMA. 2015;313:729]. JAMA. 2014;312:1033-1048. doi: 10.1001/jama.2014.10517.
181. Callaghan BC, Kerber KA, Pace RJ, Skolarus LE, Burke JF. Headaches and neuroimaging: high utilization and costs despite guidelines. JAMA Intern Med. 2014;174:819-821. doi: 10.1001/jamainternmed.2014.173.
182. Wang Z, Soo YO, Mok VC. Cerebral microbleeds: is antithrombotic therapy safe to administer? Stroke. 2014;45:2811-2817. doi: 10.1161/ STROKEAHA.114.004286.
183. Whiteley WN, Thompson D, Murray G, Cohen G, Lindley RI, Wardlaw J, Sandercock P; IST-3 Collaborative Group. Targeting recombinant tissue-type plasminogen activator in acute ischemic stroke based on risk of intracranial hemorrhage or poor functional outcome: an analysis of the Third International Stroke Trial. Stroke. 2014;45:1000-1006. doi: 10.1161/STROKEAHA.113.004362.
184. Sprint Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103-2116.